Assuntos
Dispositivos Intrauterinos , Adolescente , Adulto , Feminino , Humanos , Dispositivos Intrauterinos/efeitos adversos , Idade Materna , México , Paridade , GravidezAssuntos
Climatério , Doenças dos Genitais Femininos , Menopausa , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
PIP: Ablacton, and andro-estro-progestagen hormone combination, was administered to 59 postpartum and postcurettage patients to suppress lactation: primary inhibition was attempted in 40 cases and secondary in 19. In primary suppression, results were excellent in 83.5% of the cases, good in 10.0% and bad in 2.5%. In secondary suppression, results were excellent in all cases. The suppression of lactation was total and permanent. Tolerance to medication was very good. Because of the very small number of cases and the type of study, the study is limited to this single product.^ieng
Assuntos
Estradiol/farmacologia , Lactação/efeitos dos fármacos , Noretindrona/farmacologia , Período Pós-Parto/efeitos dos fármacos , Testosterona/farmacologia , Feminino , Humanos , GravidezAssuntos
Anticoncepcionais/administração & dosagem , Estradiol/administração & dosagem , Pregnanos/administração & dosagem , Progestinas/administração & dosagem , Adulto , Acetofenida de Algestona/administração & dosagem , Muco do Colo Uterino/efeitos dos fármacos , Preparações de Ação Retardada , Feminino , Humanos , Injeções Intramusculares , Menstruação/efeitos dos fármacos , Ovulação/efeitos dos fármacos , GravidezRESUMO
PIP: 135 women who had had at least 1 child were treated with 80 mg of mestranol and 1 mg of lynestrenol on a 22 day on, 6 day off basis for a total of 800 cycles of observation. Follow-up was done monthly. Endometrial and cervical biopsies were done and levels of pregnanediol in the urine were tested. Cycles were between 25-31 days with an average of 28. Flow averaged 3 days' duration and was slight in 53.1% of the cycles, normal in 39.3% and heavy in 2.1%. 48.3% of the cycles were characterized by no dysmenorrhea, 35.7% by slight, 11% by moderate, and 1.8% by severe. Incidence of spotting and breakthrough bleeding was slight. Side effects were also slight; nausea was present in 7.6% of the cycles, hypogastric tension in 6.6%, chloasma in 5.9%, and severe headache in 4.3%. Headaches were the only side effect reported with any regularity. No pregnancies occurred. Only 14 patients discontinued. Test results indicated that under medication the amount of pregnanediol diminished, the endometrium modified its ovulatory functions, the cervical mucus lost it ability to crystallize or stretch, and vaginal shedding was slightly modified.^ieng